Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089764 | 0.73 | PTK2 (0.33) | CA2CA9 | |
| SCHEMBL21054310 | 0.71 | — | — | |
| SCHEMBL21090807 | 0.70 | NOS3 (0.32) | CA2CA9 | |
| SCHEMBL16278731 | 0.63 | GAA (0.39) | CA2CA9 | |
| SCHEMBL16278708 | 0.62 | TP53 (0.38) | CA2CA9 | |
| SCHEMBL1449809 | 0.59 | SYK (0.30) | — | |
| SCHEMBL11745933 | 0.59 | CA9 (0.46) | CA2CA9 | |
| SCHEMBL6717839 | 0.59 | USP30 (0.32) | — | |
| SCHEMBL22686152 | 0.58 | CA2 (0.32) | CA2CA9 | |
| SCHEMBL22686153 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3720495-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | Angex Pharmaceutical, Inc. (US) | 2020-10-14 | — | — | EP | claimed |
| CN-111741964-A | Heterocyclic compounds as PRMT5 inhibitors | 安杰斯制药公司 | 2020-10-02 | — | — | CN | claimed |
| WO-2019112719-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. (US) | 2019-06-13 | — | — | WO | claimed |
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2020-11-26 | — | — | US | disclosed |
| EP-3720495-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | Angex Pharmaceutical, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| CN-111741964-A | Heterocyclic compounds as PRMT5 inhibitors | 安杰斯制药公司 | 2020-10-02 | — | — | CN | disclosed |
| WO-2019112719-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | ANGEX PHARMACEUTICAL, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369667-A1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT6 | CA2 4638/4885CA9 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.